Royal Adelaide Hospital

Ferronova raises another $6 million to advance image-guided cancer surgery

Adelaide medtech Ferronova has banked another $6 million from returning backers to advance its surgical tracer for cancer, lifting Series A funding to $17.5 million; backer parent UltraGreen.ai floated in Singapore this month.

Also movefm.com.au

Biotech Ferronova boosts Series A capital raise by $6m

Adelaide biotech Ferronova added $6 million to its Series A from prior backers, lifting the round's total to $17.5 million; backer Renew's parent Ultragreen.ai floated in Singapore this month.

Also ferronova.com.au·movefm.com.au·Biotech Dispatch·Startup Daily

Micro-X miniature CT scanner to enter clinical trials

Micro-X will trial its lightweight portable CT brain scanner at two hospitals this year; the Adelaide company's stroke technology was developed with $8 million in grant funding, as was rival EMVision's approach.

EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation

Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.

Also Brandon BioCatalyst portfolio

‘No tumour will go undetected’: Ferronova lands $11 million for its cancer hunting nanotechnology

Adelaide biotech Ferronova raised $11 million for its cancer-detection nanotechnology, with Renew Pharmaceuticals and a government CRC contributing, following an earlier $4.6 million Series A in 2020.

Also SmartCompany

South Australian biotech startup Ferronova banks $11 million to tackle cancer treatment

Adelaide cancer-focused biotech Ferronova has secured fresh backing: an investor round led by Irish strategic partner Renew Pharmaceuticals plus a federal research grant, to speed clinical trials in stomach and brain cancers.

Also SmartCompany·SmartCompany·Startup Daily·Business News Australia·Startup Daily

Ferronova secures A$11 million to advance nanotech image-guided cancer therapy

Adelaide biotech Ferronova announced an A$11 million package: an A$8 million round led by Ireland's Renew Pharmaceuticals plus an A$3 million government CRC-P grant, with existing shareholders Uniseed and Artesian also participating.

Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment

Glyscend reports encouraging Phase 1 biomarker data for its diabetes drug GLY-200, announces US FDA clearance of its investigational new drug application, and has begun enrolling patients in a Phase 2 trial.